Latest Insider Transactions at Precision Biosciences Inc (DTIL)
This section provides a real-time view of insider transactions for Precision Biosciences Inc (DTIL). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of PRECISION BIOSCIENCES INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of PRECISION BIOSCIENCES INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 31
2023
|
Dario Scimeca General Counsel and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
5,443
+6.86%
|
$0
$0.39 P/Share
|
|
Aug 18
2023
|
John Alexander Kelly Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+19.01%
|
$0
$0.48 P/Share
|
|
Jun 08
2023
|
Dario Scimeca General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
13,361
-16.33%
|
$0
$0.75 P/Share
|
|
Jun 07
2023
|
Shane Barton VP & Corporate Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
6,060
+18.06%
|
-
|
|
Jun 07
2023
|
Dario Scimeca General Counsel and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
31,771
+16.87%
|
-
|
|
Jun 07
2023
|
J. Jefferson Smith Chief Research Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,872
+0.25%
|
-
|
|
Jun 07
2023
|
John Alexander Kelly Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
47,726
+7.65%
|
-
|
|
Apr 27
2023
|
Alan List Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,771
-12.09%
|
$0
$0.79 P/Share
|
|
Apr 26
2023
|
Alan List Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
26,027
+28.82%
|
-
|
|
Apr 11
2023
|
Kevin Buehler |
BUY
Exercise of conversion of derivative security
|
Direct |
5,701
+50.0%
|
-
|
|
Mar 22
2023
|
Michael Amoroso President and CEO |
SELL
Open market or private sale
|
Direct |
46,999
-40.61%
|
$0
$0.82 P/Share
|
|
Mar 21
2023
|
Michael Amoroso President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
102,535
+46.98%
|
-
|
|
Mar 17
2023
|
John Alexander Kelly Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+7.53%
|
$0
$0.86 P/Share
|
|
Mar 06
2023
|
Alan List Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
9,473
-19.85%
|
$9,473
$1.07 P/Share
|
|
Mar 06
2023
|
Dario Scimeca General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
12,172
-19.56%
|
$12,172
$1.07 P/Share
|
|
Mar 03
2023
|
Alan List Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
29,453
+38.17%
|
-
|
|
Mar 03
2023
|
Dario Scimeca General Counsel and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
27,558
+30.69%
|
-
|
|
Mar 03
2023
|
J. Jefferson Smith Chief Research Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,576
+0.8%
|
-
|
|
Mar 03
2023
|
Shane Barton VP & Corporate Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
12,722
+37.26%
|
-
|
|
Mar 03
2023
|
John Alexander Kelly Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
51,071
+18.46%
|
-
|
|
Feb 28
2023
|
Dario Scimeca General Counsel and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
2,163
+5.87%
|
$0
$0.95 P/Share
|
|
Feb 28
2023
|
J. Jefferson Smith Chief Research Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,157
+0.63%
|
$0
$0.95 P/Share
|
|
Feb 28
2023
|
John Alexander Kelly Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,605
+6.23%
|
$0
$0.95 P/Share
|
|
Oct 17
2022
|
Michael Amoroso President and CEO |
SELL
Open market or private sale
|
Direct |
11,006
-45.46%
|
$11,006
$1.32 P/Share
|
|
Oct 15
2022
|
Michael Amoroso President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
24,208
+50.0%
|
-
|
|
Sep 23
2022
|
John Alexander Kelly Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
8,200
+4.79%
|
$8,200
$1.23 P/Share
|
|
Sep 22
2022
|
John Alexander Kelly Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
37,037
+19.31%
|
$37,037
$1.34 P/Share
|
|
Jun 22
2022
|
John Alexander Kelly Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
33,784
+22.3%
|
$33,784
$1.5 P/Share
|
|
Jun 08
2022
|
Dario Scimeca General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
9,833
-23.22%
|
$19,666
$2.06 P/Share
|
|
Jun 08
2022
|
Derek Jantz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
18,849
-0.46%
|
$37,698
$2.06 P/Share
|
|
Jun 07
2022
|
Shane Barton VP & Corporate Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
6,061
+41.01%
|
-
|
|
Jun 07
2022
|
John Alexander Kelly Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
47,728
+23.32%
|
-
|
|
Jun 07
2022
|
Dario Scimeca General Counsel and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
31,774
+29.08%
|
-
|
|
Jun 07
2022
|
Derek Jantz Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
41,744
+0.51%
|
-
|
|
Apr 27
2022
|
Alan List Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,775
-29.86%
|
$15,550
$2.1 P/Share
|
|
Apr 26
2022
|
Alan List Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
26,035
+50.0%
|
-
|
|
Mar 17
2022
|
John Alexander Kelly Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
16,677
+31.55%
|
$50,031
$3.08 P/Share
|
|
Feb 28
2022
|
John Alexander Kelly Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,714
+12.21%
|
$8,142
$3.61 P/Share
|
|
Feb 28
2022
|
Shane Barton VP & Corporate Controller |
BUY
Grant, award, or other acquisition
|
Direct |
761
+22.25%
|
$2,283
$3.61 P/Share
|
|
Feb 28
2022
|
Dario Scimeca General Counsel and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
2,049
+16.23%
|
$6,147
$3.61 P/Share
|
|
Aug 31
2021
|
John Alexander Kelly Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
998
+5.61%
|
$9,980
$10.68 P/Share
|
|
Aug 31
2021
|
Shane Barton VP & Corporate Controller |
BUY
Grant, award, or other acquisition
|
Direct |
604
+24.14%
|
$6,040
$10.68 P/Share
|
|
Aug 31
2021
|
Dario Scimeca General Counsel and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
548
+6.04%
|
$5,480
$10.68 P/Share
|
|
Jun 23
2021
|
David S. Thomson Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
30,000
-21.2%
|
$300,000
$10.65 P/Share
|
|
Jun 23
2021
|
David S. Thomson Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+17.49%
|
$30,000
$1.18 P/Share
|
|
Jun 21
2021
|
David S. Thomson Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
15,000
-11.86%
|
$150,000
$10.77 P/Share
|
|
Jun 21
2021
|
David S. Thomson Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+10.6%
|
$15,000
$1.18 P/Share
|
|
Jun 18
2021
|
David S. Thomson Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
10,000
-8.23%
|
$110,000
$11.0 P/Share
|
|
Jun 18
2021
|
David S. Thomson Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+7.6%
|
$10,000
$1.18 P/Share
|
|
Jun 17
2021
|
David S. Thomson Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
10,000
-8.23%
|
$100,000
$10.44 P/Share
|